FibroGen, Inc (NASDAQ:FGEN) had its target price lifted by research analysts at Citigroup Inc. to $65.00 in a research note issued on Tuesday, The Fly reports. The firm currently has a “top pick” rating on the biopharmaceutical company’s stock. Citigroup Inc.’s price objective suggests a potential upside of 94.61% from the company’s current price.

A number of other research analysts have also recently issued reports on FGEN. BidaskClub cut FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Jefferies Group LLC reiterated a “buy” rating and set a $75.00 price objective on shares of FibroGen in a research note on Tuesday. Stifel Nicolaus lifted their price objective on FibroGen from $38.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday. William Blair reiterated an “outperform” rating on shares of FibroGen in a research note on Monday, June 26th. Finally, Goldman Sachs Group, Inc. (The) cut FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a research note on Friday, July 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. FibroGen has an average rating of “Buy” and a consensus target price of $56.86.

Shares of FibroGen (NASDAQ FGEN) opened at 33.40 on Tuesday. FibroGen has a 52-week low of $15.60 and a 52-week high of $35.85. The stock’s market capitalization is $2.34 billion. The company has a 50-day moving average price of $32.84 and a 200-day moving average price of $27.51.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.11. The business had revenue of $26.89 million during the quarter, compared to analysts’ expectations of $26.02 million. FibroGen had a negative return on equity of 36.41% and a negative net margin of 37.60%. On average, equities analysts anticipate that FibroGen will post ($1.85) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Citigroup Inc. Boosts FibroGen, Inc (NASDAQ:FGEN) Price Target to $65.00” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/08/citigroup-inc-boosts-fibrogen-inc-nasdaqfgen-price-target-to-65-00.html.

In other news, Director Kalevi Kurkijarvi sold 2,000 shares of the business’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $27.40, for a total value of $54,800.00. Following the completion of the transaction, the director now owns 36,000 shares in the company, valued at $986,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Pat Cotroneo sold 28,346 shares of the business’s stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $33.97, for a total value of $962,913.62. Following the completion of the transaction, the vice president now owns 170,666 shares of the company’s stock, valued at approximately $5,797,524.02. The disclosure for this sale can be found here. Insiders sold 409,974 shares of company stock valued at $12,647,338 in the last 90 days. Company insiders own 14.90% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. DekaBank Deutsche Girozentrale acquired a new position in FibroGen during the first quarter valued at $1,133,000. American Century Companies Inc. boosted its stake in FibroGen by 35.0% in the first quarter. American Century Companies Inc. now owns 250,051 shares of the biopharmaceutical company’s stock worth $6,164,000 after buying an additional 64,760 shares during the period. Algert Global LLC boosted its stake in FibroGen by 6.4% in the first quarter. Algert Global LLC now owns 24,322 shares of the biopharmaceutical company’s stock worth $600,000 after buying an additional 1,466 shares during the period. Wells Fargo & Company MN boosted its stake in FibroGen by 29.0% in the first quarter. Wells Fargo & Company MN now owns 62,037 shares of the biopharmaceutical company’s stock worth $1,529,000 after buying an additional 13,928 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in FibroGen by 58.1% in the first quarter. Russell Investments Group Ltd. now owns 33,627 shares of the biopharmaceutical company’s stock worth $829,000 after buying an additional 12,354 shares during the period. Hedge funds and other institutional investors own 43.45% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

The Fly

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.